Table 1 Clinicopathological and Preoperative Imaging Characteristics of Patients with Pericolic Lymph Nodes Metastasis Beyond 10 cm Proximal to The Tumor and Those without Metastasis on CT Scan
Variables | All patients (n = 312) | pPCN group (n = 14) | nPCN group (n = 298) | |
|---|---|---|---|---|
Value | P value | |||
Age (year) a | 60 (27–94) | 55.5 (44–79) | 61 (27–94) | 0.356 |
Sex | 0.239 | |||
Male | 199 (63.8%) | 11 (78.6%) | 188 (63.1%) | |
Female | 113 (36.2%) | 3 (21.4%) | 110 (36.9%) | |
BMI (kg/m2)a | 23.23 (15.07–32.33) | 23.54 (17.72–27.68) | 23.15 (15.07–32.33) | 0.95 |
CEA (ng/ml)a | 3.41 (0–1000) | 4.34 (0.97–258.40) | 3.41 (0–1000) | 0.721 |
Distance from anal verge (cm) a | 6 (1–12) | 7 (3–12) | 6 (1–12) | 0.766 |
Preoperative neoadjuvant chemoradiotherapy | 0.028 | |||
Radiotherapy | 31 (9.9%) | 4 (28.6%) | 27 (9.1%) | |
Chemotherapy | 15 (4.8%) | 2 (14.3%) | 13 (4.4%) | |
Chemoradiotherapy | 54 (17.3%) | 1 (7.1%) | 53 (17.8%) | |
Operation procedure | 1.00 | |||
Laparoscopy | 282 (90.4%) | 13 (92.9%) | 269 (90.3%) | |
Open | 26 (8.3%) | 1 (7.1%) | 25 (8.4%) | |
Type of surgery | 0.331 | |||
Dixon | 209 (67%) | 9 (64.3%) | 200 (67.1%) | |
ELAPE or Miles | 51 (16.3%) | 4 (28.6%) | 47 (15.7%) | |
Hartmann | 16 (5.1%) | 0 (0%) | 16 (5.4%) | |
ISR | 36 (11.5%) | 1 (7.1%) | 35 (11.7%) | |
Operation time (min)a | 180 (80–540) | 177.5 (120–350) | 180 (80–540) | 0.459 |
Blood Loss (ml)a | 40 (5–450) | 40 (20–150) | 40 (5–450) | 0.736 |
Postoperative hospital stay (days)a | 8 (3–48) | 8 (5–20) | 8 (3–48) | 0.946 |
Time to tolerance to liquid food (hours)a | 72 (10–432) | 84 (24–432) | 72 (10–336) | 0.399 |
Postoperative complications | 65 (20.8%) | 2 (14.3%) | 63 (21.1%) | 0.779 |
Postoperative adjuvant chemoradiotherapy | 0.001 | |||
Chemotherapy | 138 (44.2%) | 8 (57.1%) | 130 (43.6%) | |
Chemoradiotherapy | 24 (7.7%) | 5 (35.7%) | 19 (6.4%) | |
No. of mesenteric lymph nodesa | 4.0 (0–20) | 3.5 (2.0–14.0) | 4.0 (0–20) | 0.238 |
The maximum short-axis diameter of the largest mesenteric lymph node (mm)a | 5.5 (0–19.0 | 7.4 (0–15.1) | 5.5 (0–19.0) | 0.008 |
Presence of mesenteric lymph nodes with the maximum short-axis diameter ≥ 8 mm | 56 (17.9%) | 7 (50%) | 49 (16.4%) | 0.005 |
Clinical T stage n (%)b | 0.049 | |||
T1–2 | 60 (19.2%) | 0 (0.0%) | 60 (20.1%) | |
T3–4 | 252 (80.8%) | 14 (100%) | 238 (79.9%) | |
Clinical N stage n (%)b | 0.017 | |||
N0 | 149 (47.8%) | 3 (21.4%) | 146 (49.0%) | |
N1 | 124 (39.7%) | 5 (35.7%) | 119 (39.9%) | |
N2 | 39 (12.5%) | 6 (42.9%) | 33 (11.1%) | |
Clinical M stage n (%) | 0.083 | |||
M0 | 288 (92.3%) | 11 (78.6%) | 277 (92.9%) | |
M1 | 24 (7.7%) | 3 (21.4%) | 21 (7.1%) | |
AJCC stage n (%) c | 0.018 | |||
I | 50 (16%) | 0 (0.0%) | 50 (16.8%) | |
II | 94 (30.1%) | 3 (21.4%) | 91 (30.5%) | |
III | 144 (46.2%) | 8 (57.2%) | 136 (45.6%) | |
IV | 24 (7.7%) | 3 (21.4%) | 21 (7.1%) | |